公开(公告)号：EP2470560A1

公开(公告)日：2012-07-04

申请号：EP10749982.4

申请日：2010-08-27

申请人： Research Development Foundation

发明人： VALE, Wylie, W. ,  VAUGHAN, Joan ,  DONALDSON, Cindy ,  FISCHER, Wolfgang ,  RIVIER, Jean, E.

IPC分类号： C07K14/575

CPC分类号： A61K38/2228 ,  C07K14/4705 ,  C07K14/57509 ,  Y10T428/13

摘要： Disclosed are polypeptides that are analogs of urocortin 2 that have pharmacological activity similar to urocortin 2 but have improved water solubility compared to urocortin 2, and pharmaceutical compositions of the polypeptides of the present invention. Also disclosed are polynucleotides encoding the polypeptides, and methods of treating pathophysiological states employing pharmaceutical compositions of the polypeptides and polynucleotides of the present invention. In addition, disclosed are vectors and host cells that include a nucleic acid encoding a polypeptide of the present invention, and kits that include pharmaceutical compositions of the present invention.

公开(公告)号：EP2259793A2

公开(公告)日：2010-12-15

申请号：EP09739199.9

申请日：2009-04-30

申请人： Neutron Row

发明人： EVANS-FREKE, Stephen

IPC分类号： A61K38/22 ,  A61P35/00

CPC分类号： A61K38/2228 ,  A61K31/549 ,  A61K2300/00

摘要： Provided herein is a method for treating cancer in a human by administering a high dose of corticotropin-releasing factor (CRF) for a period of time exceeding 3 days.

公开(公告)号：EP1968624A2

公开(公告)日：2008-09-17

申请号：EP07700413.3

申请日：2007-01-05

申请人： Aimsco Limited

发明人： MCINTOSH, Deirdre

IPC分类号： A61K38/17 ,  A61K38/22

CPC分类号： A61K38/2228 ,  A61K38/16 ,  A61K38/1709 ,  A61K38/1774 ,  A61K38/1841 ,  A61K38/2066 ,  A61K38/22 ,  A61K38/33 ,  A61K38/34 ,  A61K38/35 ,  A61K2300/00

摘要： We describe methods of treatment of HIV using proopiomelanocortin (POMC) and corticotropin releasing factor (CRF) peptides and their products, as well as uses of such peptides in the preparation of medicaments.

公开(公告)号：EP1405082A2

公开(公告)日：2004-04-07

申请号：EP02758248.5

申请日：2002-06-19

申请人： Aventis Pharma Deutschland GmbH

发明人： KOSTENIS, Evi ,  BUSCH, Andreas ,  REGITZ-ZAGROSEK, Vera

IPC分类号： G01N33/68 ,  C07K14/575 ,  A61K38/22 ,  C12Q1/68 ,  C12Q1/25

CPC分类号： C12Q1/6883 ,  A61K38/2228 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/74 ,  G01N2333/5751 ,  G01N2500/00

摘要： The invention relates to a method for identifying a compound that modifies the activity of the urotensin II receptors by influencing those genes or gene products that are associated with the composition, formation or degradation of the extracellular matrix.

公开(公告)号：EP0724637B2

公开(公告)日：2002-06-05

申请号：EP95925271.9

申请日：1995-06-14

申请人： NEUROCRINE BIOSCIENCES, INC.

发明人： CHALMERS, Derek ,  LOVENBERG, Timothy W. ,  OLTERSDORF, Tilman ,  LIAW, Chen Wang ,  GRIGORIADIS, Dimitri E. ,  DE SOUZA, Errol B.

IPC分类号： C12N15/12 ,  C07K14/72 ,  C07K16/28 ,  A61K38/17 ,  G01N33/68 ,  C12Q1/68

CPC分类号： C07K14/72 ,  A61K38/2228

摘要： The present invention provides isolated nucleic acid molecules encoding CRF2 receptors, recombinant expression vectors and host cells suitable for expressing such receptors, as well as compositions and methods which utilize such receptors.

公开(公告)号：EP0724637B1

公开(公告)日：1998-09-16

申请号：EP95925271.9

申请日：1995-06-14

申请人： NEUROCRINE BIOSCIENCES, INC.

发明人： CHALMERS, Derek ,  LOVENBERG, Timothy W. ,  OLTERSDORF, Tilman ,  LIAW, Chen Wang ,  GRIGORIADIS, Dimitri E. ,  DE SOUZA, Errol B.

IPC分类号： C12N15/12 ,  C07K14/72 ,  C07K16/28 ,  A61K38/17 ,  G01N33/68 ,  C12Q1/68

CPC分类号： C07K14/72 ,  A61K38/2228

摘要： The present invention provides isolated nucleic acid molecules encoding CRF2 receptors, recombinant expression vectors and host cells suitable for expressing such receptors, as well as compositions and methods which utilize such receptors.

公开(公告)号：EP0494256A4

公开(公告)日：1992-08-12

申请号：EP90915568

申请日：1990-09-25

申请人： US HEALTH

发明人： STERNBERG, ESTHER, M. ,  WILDER, RONALD, L. ,  CHROUSOS, GEORGE, P. ,  GOLD, PHILIP, W.

IPC分类号： A61K31/135 ,  A61K31/495 ,  A61K31/57 ,  A61K38/00 ,  A61K38/11 ,  A61K38/22 ,  A61K38/27 ,  A61K45/00 ,  A61P29/00 ,  G01N33/50 ,  G01N33/53 ,  G01N33/74 ,  G01N1/00 ,  A61K37/66 ,  A61K45/05 ,  G01N33/48

CPC分类号： G01N33/5091 ,  A61K38/11 ,  A61K38/2006 ,  A61K38/2228 ,  A61K38/31 ,  G01N2800/102

摘要： The present invention relates to a diagnostic test for testing susceptibility of individuals to inflammatory diseases such as rheumatoid arthritis and to means to evaluate potential treatment of arthritis with therapeutic agents directed at the central nervous system (CNS), designed to by-pass the CNS defect. The invention also provides means for evaluating and predicting response to stress in individuals. A counter-regulatory feedback loop exists between the immune and central nervous systems, in which the immune or pro-inflammatory mediators stimulate corticotropin-releasing hormone (CRH) activation of the hypothalamic-pituitary-adrenal (HPA) axis hormonal cascade. The resultant increase in plasma glucocorticoids serves to restrain and limit the intensity of the inflammatory-immune response, through the potent immunosuppressive/anti-inflammatory actions of the glucocorticoids.

公开(公告)号：EP0484340A1

公开(公告)日：1992-05-13

申请号：EP90909011.0

申请日：1990-05-30

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： WEI, Edward, T.

IPC分类号： A01D1 ,  A01N1 ,  A61K38 ,  A61P3 ,  C07K14

CPC分类号： A61K38/2228 ,  A01N1/021 ,  A01N1/0226

摘要： L'administration d'un facteur (d'un sel ou d'un analogue de celui-ci) de libération de corticotropine diminue la fuite de composants du sang dans les tissus cérébraux, résultant de divers états médicaux défavorables, et réduit le saignement lorsque l'on coupe et lorsque l'on manipule des tissus musculaires par exemple en chirurgie plastique et réparatrice. Un procédé de traitement des lésions ou de maladies du cerveau, du système nerveux central, ou de la musculature d'un patient, dans lesquelles l'oedème constitue un facteur, consiste à administrer au patient un facteur (un sel ou un analogue) de libération de corticotropine en une quantité efficace pour réduire la perméabilité vasculaire dans le cerveau lésé ou malade, les tissus ou la musculature du système nerveux, et ainsi à réduire l'oedème. L'administration selon le procédé peut avoir lieu environ deux heures avant la chirurgie, et jusqu'à trois jours après les lésions.

公开(公告)号：EP2814513B1

公开(公告)日：2017-12-20

申请号：EP13749674.1

申请日：2013-02-13

申请人： The Regents of the University of California

发明人： HAMMOND, H., Kirk ,  GAO, Mei, Hua

IPC分类号： A61K48/00 ,  A61K38/17 ,  A61K38/16 ,  A61K9/08 ,  A61K9/06 ,  A61P17/00 ,  A61P9/00

CPC分类号： C12N15/861 ,  A61K31/436 ,  A61K31/65 ,  A61K38/2221 ,  A61K38/2228 ,  A61K38/2242 ,  A61K38/25 ,  A61K38/30 ,  A61K38/52 ,  A61K47/6901 ,  A61K48/00 ,  A61K48/005 ,  C07K14/075 ,  C07K14/57509 ,  C07K14/65 ,  C12N15/86 ,  C12N2710/10343 ,  C12N2750/14143 ,  C12N2830/003

摘要： In alternative embodiments, the invention provides methods for treating, ameliorating or protecting (preventing) an individual or a patient against a disease, an infection or a condition responsive to an increased paracrine polypeptide level in vivo comprising: providing a paracrine polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence; or an expression vehicle, a vector, a recombinant virus, or equivalent, having contained therein a paracrine-encoding nucleic acid or gene, and the expression vehicle, vector, recombinant virus, or equivalent can express the paracrine-encoding nucleic acid or gene in a cell or in vivo; and administering or delivering the paracrine polypeptide -encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence, or the expression vehicle, vector, recombinant virus, or equivalent, to an individual or a patient in need thereof, thereby treating, ameliorating or protecting (preventing) the individual or patient against the disease, infection or condition responsive to an increased paracrine polypeptide level.

公开(公告)号：EP2522351B1

公开(公告)日：2017-09-06

申请号：EP12179553.8

申请日：2008-06-13

申请人： RESEARCH DEVELOPMENT FOUNDATION

发明人： Rissman, Robert A. ,  Lee, Kuo-Fen ,  Vale, Wylie W. ,  Sawchenko, Paul E.

IPC分类号： A61K31/519 ,  A61K38/22 ,  A61K38/57 ,  A61K45/06 ,  G01N33/68 ,  A61P25/28

CPC分类号： A61K31/519 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0318 ,  A61K9/0019 ,  A61K38/2228 ,  A61K45/06 ,  G01N33/6896 ,  G01N2440/14 ,  G01N2500/00 ,  G01N2800/2814 ,  G01N2800/2821 ,  A61K2300/00

摘要： Methods for treating or preventing tauopathies and/or A² amyloidosis by modulating CRF receptor signaling. Accumulation of hyperphosphorylated tau protein in the CNS may be reduced by administration of CRF-R1 selective antagonists and/or CRF-R2 selective agonists. For example, in some aspects, methods for preventing the onset of Alzheimer's disease by administration of CRF-R1 selective antagonists are provided.

摘要翻译： 通过调节CRF受体信号传导来治疗或预防tau蛋白病和/或A 2淀粉样变性的方法。 通过施用CRF-R1选择性拮抗剂和/或CRF-R2选择性激动剂，可以降低CNS中过度磷酸化tau蛋白的积累。 例如，在一些方面，提供了通过施用CRF-R1选择性拮抗剂来预防阿尔茨海默氏病发作的方法。